Peking University Cancer Hospital 1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma Beijing, China
Auto-generated profile, based on publicly available information
Yue Yang
Peking University Cancer Hospital 1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma Beijing, China
More than 70% of melanomas in China are acral or mucosal subtypes, which respond poorly to immune checkpoint inhibitors (ICI). Tumor-infiltrating lymphocyte (TIL) therapy is active in metastatic melanoma, with evidence from cutaneous-predominant cohorts and immune correlates undefined in Asian patients. We evaluated an autologous TIL therapy LM103 in Chinese patients with refractory metastatic melanoma. Fourteen patients received lymphodepleting chemotherapy followed by LM103 infusion (3.58–19.47 × 1010 cells) and high-dose interleukin 2 (IL2). Characteristics of baseline tumor, TIL products, and pre-/postinfusion peripheral blood were analyzed. All patients experienced myelosuppression and capillary leak syndrome. Grade 3 to 4 treatment-emergent adverse events (TEAE) included leukopenia (85.7%), neutropenia (78.6%), lymphopenia (78.6%), fever (71.4%), and thrombocytopenia (57.1%). The objective response rate (ORR) was 35.7% [95% confidence interval (CI), 12.76–64.86], and the disease control rate (DCR) was 85.7% (95% CI, 57.19–98.22). The median progression-free survival (PFS) was 4.52 months (95% CI, 2.07–14.31), and the median overall survival (OS) was 16.58 months (95% CI, 5.16–not estimable). Baseline tumor immune infiltration and tumor mutational burden (TMB) were not associated with clinical outcome. LM103 induced marked peripheral T-cell receptor (TCR) repertoire remodeling, with >60% of infused TIL clones detectable at 6 months. Patients with superior outcomes demonstrated greater expansion and persistence of dominant TIL clones. Genes favoring T-cell tumor infiltration were upregulated in TILs of patients with longer PFS. LM103 showed manageable safety and encouraging antitumor activity. Clinical benefit was associated with sustained in vivo clonal persistence and upregulated genes favoring tumor re-infiltration of infused TILs. The trial registration number is CTR20233999. Significance: In a phase I trial, clinical benefit of autologous TIL therapy with LM103 is associated with sustained in vivo clonal persistence and upregulation of genes favoring tumor re-infiltration of infused TILs.